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PAPER
Clinimetric evaluation of a new overall disability scale in
immune mediated polyneuropathies
I S J Merkies, P I M Schmitz, F G A van der Meché, J P A Samijn, P A van Doorn, for the
Inflammatory Neuropathy Cause and Treatment (INCAT) group
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J Neurol Neurosurg Psychiatry 2002;72:596–601
Objectives: To determine the validity, reliability, and responsiveness of a new overall disability sum
score in immune mediated polyneuropathies.
Methods: Three impairment measures (MRC sum score, sensory sum score, grip strength (Vigorimeter))
and three disability scales (an overall disability sum score (ODSS), Hughes’ functional scale (f score),
Rankin scale) were assessed in a cross sectional group of 113 clinically stable patients (83 with
Guillain–Barré syndrome, 22 with chronic inflammatory demyelinating polyneuropathy (CIDP), eight
with a gammopathy related polyneuropathy). The ODSS was also used serially in 20 patients with
recently diagnosed Guillain–Barré syndrome (n = 7) or CIDP (n = 13) and changing clinical
conditions. Multiple regression studies were performed to compare the impact of impairment
disturbances (independent variables) on the various disability scales (dependent variable).
Results: Moderate to good construct validity (stable group: Spearman’s rank test (absolute values),
r = 0.41–0.79; longitudinal group: multiple correlation coefficient, R = 0.69–0.89; p < 0.006 for all
associations) and reliability (intraclass correlation coefficient, R = 0.90–0.95; p < 0.0001) were dem-
onstrated for the ODSS. Its SRM values were high (> 0.8), indicating good responsiveness. Impairment
measures accounted for a higher variance proportion of the ODSS compared with the f score and
Rankin (R = 0.64 v 0.56 and 0.45, respectively).
Conclusions: All clinimetric requirements were met by the overall (arm and leg) disability sum score in
immune mediated polyneuropathies. Its use is therefore suggested in evaluating immune mediated
polyneuropathies.
Clinical assessment in patients with Guillain–Barré syn-drome, chronic inflammatory demyelinating polyneu-ropathy (CIDP), and polyneuropathy associated with a
monoclonal gammopathy of undetermined significance
(MGUSP) has traditionally been focused on impairment and
less often on disability.1 2 The most commonly used impair-
ment scales are the motor scales based on the Medical
Research Council (MRC) grading system, and different
sensory outcome measures including various modes of
sensation.3 Disability, on the other hand, has primarily been
evaluated using the (modified) Hughes’ functional grading
scale (f score) and the (modified) Rankin scale.4–7 The
clinimetric properties of the f score have been demonstrated
in patients with Guillain–Barré syndrome,7 but no formal
clinimetric evaluation of the Rankin scale has been under-
taken in patients with polyneuropathies. Despite their
simplicity and obvious face value, clinical use of the Hughes’
and Rankin scales is somewhat limited, as their emphasis is
strongly directed towards mobility and they provide little
information about arm function. Arm dysfunction in immune
mediated polyneuropathies may contribute to disability,8 so
disability measures ought to address the arms as well as the
legs in these conditions. Nevertheless, only a few studies have
evaluated arm disabilities in these disorders.9–13
In a recent study, a disability scale was applied in these con-
ditions that described functional disturbances of both the legs
and the arms.12 This overall disability sum score (ODSS)—
forming part of the Guy’s neurological disability scale—
showed a significant correlation with the “INCAT” sensory
sum score, thereby proving its validity (table 1).12 14 However,
further clinimetric evaluation of this comprehensive disability
scale is required before it is recommended for general use in
patients with immune mediated polyneuropathies.15–18
Prompted by these observations, we investigated the
construct validity, reliability, and responsiveness of the ODSS.
Validity is defined as the relation between the concept to be
measured and the scale used to assess that concept. It usually
relies on expert judgments (content and face validity), by
demonstrating a high correlation between the scale and a gold
standard (criterion validity) or, in the absence of a gold stand-
ard, by examining the degree of association between a scale
and other widely used measures (construct validity).15 16
Reliability addresses the internal consistency in multi-item
scales and the ability of a scale to demonstrate reproducibility
of the scores by the same (intraobserver) or a different exam-
iner (interobserver), or by the same patient (test–retest
reliability) in the case of self rating scales.15 16
Responsiveness is defined as the ability of a scale to detect
meaningful clinical changes over time when evaluating the
benefits of a medical intervention.15 17 18 A statistic and heuris-
tic approach in examining responsiveness has been
described.17 Statistical responsiveness captures the ability of
an instrument to measure any change, irrespective of its
relevance; this form of responsiveness can be assessed within
a group of patients receiving the same treatment or between
groups of patients being treated in different ways.15 17 18
Heuristic techniques are based on comparing changes as
assessed by an outcome measure with an external indicator—
for example, patients judging their clinical condition as being
worse, stable, or improved.17
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Finally, the ODSS was compared with the f score and
Rankin scale to determine which of these disability measures
captures most adequately the impairments leading to disabil-
ity.
METHODS
Patients
A cross sectional group of 113 patients (83 with Guillain–
Barré syndrome, 22 with CIDP, and eight with MGUSP) in
stable clinical condition were recruited from the Rotterdam
immune mediated polyneuropathy databank and the Dutch
GBS study group (stable group). Patients with Guillain–Barré
syndrome, CIDP, or MGUSP were recruited, as it was argued
that these disorders represent parts of a continuum with
respect to their pattern of neuromuscular dysfunction.2 These
selected patients had residual symptoms or signs of their
illness, representing a broad range of disability. Nine CIDP
patients required interval treatment, ranging from weeks to
months, with intravenous immunoglobulin. On this treatment
their clinical condition has been stable for more than six
months. Six patients with MGUSP (three involving IgG, two
IgM, and one IgG+IgM) had a demyelinating polyneuropathy,
with minor concurrent axonal damage in three. An axonal
polyneuropathy was diagnosed in the remaining two patients
with MGUSP (one IgA type and one IgG type).
Twenty consecutive patients with recently diagnosed
sensory-motor Guillain–Barré syndrome (n = 7) or CIDP
(n = 13) and changing clinical condition were enrolled to
investigate the responsiveness of the ODSS (longitudinal
group).
All Guillain–Barré and CIDP patients met the international
criteria for their illness.19 20 The diagnosis MGUSP was
established after excluding all other known causes of
gammopathy and polyneuropathy.21
Assessment tools/scales
The MRC sum score is a summation of the MRC grades (range,
0–5) given in full numbers of the following muscle pairs:
upper arm abductors, elbow flexors, wrist extensors, hip flex-
ors, knee extensors, and foot dorsal flexors.7 The MRC sum
score ranges from 0 (“total paralysis”) to 60 (“normal
strength”). Good validity and interobserver reliability for this
scale have been demonstrated in patients with Guillain–Barré
syndrome.7
The “INCAT” sensory sum score was recently introduced and
extensively evaluated clinimetrically in patients with immune
mediated polyneuropathies.12 In brief, this sensory scale com-
prises pin prick and vibration sense plus a two point discrimi-
nation value in the arms and legs, and ranges from 0 (“normal
sensation”) to 20 (“most severe sensory deficit”).12
The Vigorimeter (Martin Co, Tuttlingen, Germany) is a hand
held dynamometer for measuring grip strength.9 Good
clinimetric properties have been demonstrated in patients
with immune mediated polyneuropathies.9
The overall disability sum score (ODSS) is composed of a
recently published arm and leg disability scale with a total
score ranging from 0 (“no signs of disability”) to 12 (“most
severe disability score”) (table 1).12 14 The ODSS comprises a
good functional description of the arms and legs in a checklist
form suitable for interviewing patients. Daily arm activities
like dressing the upper part of the body, doing and undoing
Table 1 The overall disability sum score (ODSS)
Arm disability scale – function checklist Not affected
Affected but not
prevented Prevented
Dressing upper part of body (excluding buttons/zips) O O O
Washing and brushing hair O O O
Turning a key in a lock O O O
Using knife and fork (/spoon—applicable if the patient never uses knife and fork) O O O
Doing/undoing buttons and zips O O O
Arm grade
0 = Normal
1 = Minor symptoms or signs in one or both arms but not affecting any of the functions listed
2 = Moderate symptoms or signs in one or both arms affecting but not preventing any of the functions listed
3 = Severe symptoms or signs in one or both arms preventing at least one but not all functions listed
4 = Severe symptoms or signs in both arms preventing all functions listed but some purposeful movements still possible
5 = Severe symptoms and signs in both arms preventing all purposeful movements
Leg disability scale – function checklist No Yes Not applicable
Do you have any problem with your walking? O O O
Do you use a walking aid? O O O
How do you usually get around for about 10 metres?
Without aid O O O
With one stick or crutch or holding to someone’s arm O O O
With two sticks or crutches or one stick or crutch and holding to someone’s arm O O O
With a wheelchair O O O
If you use a wheelchair, can you stand and walk a few steps with help? O O O
If you are restricted to bed most of the time, are you able to make some
purposeful movements?
O O O
Leg grade
0 = Walking is not affected
1 = Walking is affected but does not look abnormal
2 = Walks independently but gait looks abnormal
3 = Usually uses unilateral support to walk 10 metres (25 feet) (stick, single crutch, one arm)
4 = Usually uses bilateral support to walk 10 metres (25 feet) (sticks, crutches, two arms)
5 = Usually uses wheelchair to travel 10 metres (25 feet)
6 = Restricted to wheelchair, unable to stand and walk few steps with help but able to make some purposeful leg movements
7 = Restricted to wheelchair or bed most of the day, preventing all purposeful movements of the legs (eg, unable to reposition legs in bed)
Overall disability sum score = arm disability scale (range 0–5) + leg disability scale (range 0–7); overall range: 0 (no signs of disability) to 12 (maximum
disability).
For the arm disability scale: allocate one arm grade only by completing the function checklist. Indicate whether each function is “affected,” “affected but
not prevented,” or “prevented.”
For the leg disability scale: Allocate one leg grade only by completing the functional questions.
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buttons and zips, washing and brushing hair, using a knife
and fork, and turning a key in a lock are scored as being “not
affected,” “affected but not prevented,” or “prevented.” Subse-
quently, these results are translated into an arm grade (score
range, 0 (normal arm abilities) to 5 (severe symptoms and
signs in both arms preventing all purposeful movements)).
The leg scale highlights problems of walking, taking into
account the use of a device. The results are also translated into
a leg grade (score range, 0 (walking is not affected) to 7
(restricted to wheelchair or bed most of the day, preventing all
purposeful movements of the legs) (table 1).14 The selected
arm and leg disability scales are subsets of a more
comprehensive Guy’s neurological disability scale.14 Good
clinimetric requirements have recently been demonstrated for
all components of the Guy’s scale in patients with multiple
sclerosis.14
The modified Hughes’ functional grading scale (f score)
assesses the functional ability of the patient, with a strong
emphasis on mobility.7 The f score of the patients included in
this study ranged from 0 (no symptoms or signs) to 5 (requir-
ing artificial ventilation for at least part of the day).7
The Rankin scale has primarily been used in patients with
stroke.6 The grades of this scale range from 0 (no symptoms at
all) to 5 (severe disability, bedridden, incontinent, and requir-
ing constant nursing care and attention).6 No formal
clinimetric evaluation of this scale has been undertaken in
patients with immune mediated polyneuropathies.
Test procedures
General aspects
All participants gave their informed consent and were studied
in a quiet and comfortably warm room at our outpatient clinic.
The assessments were done in a random order. For the assess-
ment of general strength, joint and limb position was
standardised, and the point at which counterforce was applied
was defined before the start of the study and used when
examining each muscle group. Sensory function was exam-
ined in triplicate under prescribed standardised conditions,
with the patient lying in a supine position.12 For the
assessment of grip strength with the Vigorimeter, all patients
were examined under standardised conditions.9 22
The study took place between December 1998 and January
2000 and was performed on behalf of INCAT, a group of senior
European neurologists with a special interest in neuro-
immunological illnesses.
Validity and reliability
We undertook several different forms of validation of the
ODSS.15 16 “Validity by assumption” (that is, face and content
validity) involved a review of all aspects of the ODSS by the
INCAT expert panel.15 16 The correlation between the ODSS
and other outcome measures was investigated by correlation
and regression studies (construct validity). To assess the
reliability and validity of the ODSS in the stable group of 113
patients, two neurologists and six experienced residents in
neurology formed 28 different couples. Preceding the study, all
investigators received instructions in assessing the outcome
measures. Twenty seven (“variable”) couples investigated a
total of 68 patients (two to three patients for each couple). The
remaining 45 stable patients were examined by the “experi-
enced” couple (IM + JS). The latter couple was formed to
examine the effect of training (and thus a possible increase in
reliability) resulting from frequent use of the ODSS.
The patients were examined on two different occasions in
our outpatient clinic. During the first visit the two members of
an appointed pair performed their scores independently and
consecutively (usually within two hours) (interobserver
measures). Within two to four weeks, the patient returned for
a second visit and only one investigator of the earlier assigned
pair examined the patient again (intraobserver values), with-
out having access to previous results. The assessment
sequence at entry and the examination at the second visit
were equally distributed among the members of an assigned
couple. Eventually, each member of a couple examined
approximately the same number of patients. With the excep-
tion of the f score, all scales were assessed at each visit in all
patients. For the validity and the regression model studies,
only the recruited scales’ values at one examination were
used.
Responsiveness
Twenty consecutive patients were examined longitudinally by
the same clinician (IM). The ODSS was assessed at study entry
and at the weeks 2, 4, 8, 12, 16, 21, 26, 32, 40, and 52 of follow
up, with additional clinical investigations if necessary. At each
visit, the patients were requested to judge whether their clini-
cal condition had deteriorated (grade 1), remained stable
(grade 2), or improved (grade 3) when compared with the last
visit (“clinical judgment scores”). At study entry, the patients
compared their clinical condition against their physical status
in the two weeks before the start of the study.
Statistics
Validity and reliability
In the cross sectional stable group, the correlation between
ODSS and the other outcome measures was analysed using
Spearman’s rank correlation test. Random effects linear
regression analyses were also performed between the ODSS
and the other scales in the longitudinal group, taking into
account the associations caused by the longitudinal structure.
The linear regression analyses were done using the program
“xtreg” in STATA 6.0 (Stata Corporation, 1997. Stata Statistical
Software: release 6.0. College Station, Texas, USA), which is
based on a cross sectional time series regression model as
described by Dwyer and Feinleib.23 The scores obtained are
presented as multiple correlation coefficients. The inter-rater
and intrarater reliability of the ODSS was quantified by
estimation of the intraclass correlation coefficient using a one
way random effects analysis of variance model for the two
investigator groups (“experienced” and “variable”).
Responsiveness
Responsiveness was examined in both statistical and heuristic
forms.17 Statistical responsiveness was investigated by calcu-
lating the standardised response mean (SRM) scores for the
ODSS at various arbitrarily chosen occasions during follow up
(weeks 12, 26, 40, and 52).24 The SRM is equal to the mean
change in score divided by the standard deviation of the
change in score:
SRM = µi − µo/SD(µi− µo)
where µi = mean ODSS value of the longitudinally examined
group at week = i, and µo = mean ODSS value at week = 0
[entry]).24 A value between 0.5 and 0.8 is considered moderate
responsiveness, and 0.8 or greater as high responsiveness.24 25
For each patient, the differences between every pair of
consecutive ODSS values were calculated (= ODSS value at
visit i minus ODSS value at visit (i−1) = ODSS changes).
These differences were associated with the corresponding
clinical judgment scores using “xtreg,” thus investigating the
heuristic form of responsiveness.17 23
All analyses were performed using Stata 6.0 for Windows
97. A probability (p) value of < 0.05 was considered
statistically significant.
Comparative study
In the stable group, univariate and multivariate linear
regression analyses were done to determine which disability
measure (ODSS, f score, or Rankin scale—dependent vari-
ables) had the strongest association with a group of
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impairment measures (MRC sum score, INCAT sensory sum
score, grip strength by the Vigorimeter—independent vari-
ables). If necessary, a transformation of the dependent
variable (for example, by logarithmic conversion) was done to
obtain a normal distribution. We concentrated on univariate
regression studies, aiming for the best fit between dependent
and independent variables. This was achieved through
systematic evaluation of the graphs constructed from the lin-
ear regression studies, which included a restriction cubic
spline function on the independent variable.26 Subsequently,
multivariate linear regression analyses were performed, with a
backward stepwise eliminating strategy to construct the final
models. The strength of association between the dependent
variable and explanatory variables was presented as R2—the
fraction of variance explained by the independent variable
from a regression model. Only the results that included the
right hand grip strength values are presented, as these
findings were similar to those incorporating the left hand
values.
RESULTS
General aspects
All eight examiners concluded that the ODSS was easily
applicable and required less than two minutes for completion.
The stable group of patients (54 women and 59 men) had a
median duration of symptoms before the start of the study of
5.1 years. Seven of these patients were bed bound and 14
required assistance or a device to walk short distances. The
remaining 92 patients could walk independently. The corre-
sponding median values and ranges for all scales in these
patients are presented in table 2.
Validity and interobserver/intraobserver reliability
The correlation studies comparing the ODSS with the other
scales and the reliability values for the ODSS in the stable
group of patients are presented in table 3. Significant validity
and good reliability were demonstrated for the ODSS by the
“experienced” and “variable” couples of investigators. In the
longitudinal group, significant associations were also obtained
between the ODSS and other measures: ODSS v MRC sum
score: random effects analysis of variance, R = 0.89; v sensory
sum score: R = 0.74; v grip strength: R = 0.72 (right hand)
and R = 0.69 (left hand); v f score: R = 0.86; v Rankin:
R = 0.88 (p < 0.0001 for all associations).
Responsiveness
Eight women and 12 men were examined longitudinally. At
study entry, four were bed bound, one requiring artificial ven-
tilation, and nine were unable to walk independently. All
patients experienced general loss of strength, sensory
disturbances, and deficit in their daily functional activities. We
completed 201 visits during a follow up period of 40 to 58
weeks (median 52). Nineteen patients completed a one year
follow up. With the exception of one patient with Guillain–
Barré syndrome who only experienced mild symptoms, all
patients had received initial treatment with intravenous
immunoglobulin (0.4 g/kg body weight/day for five consecu-
tive days). All but one patient with CIDP showed good
functional improvement on intravenous immunoglobulin
during follow up. The non-responder received a treatment
Table 2 Basic characteristics of patients with immune
mediated polyneuropathies
Stable group of patients (n=113; GBS 83, CIDP 22, MGUSP 8)
Age at start of the study (years) 56 (14 to 84)
MRC sum score (score range 0 to 60) 54 (18 to 60)
INCAT sensory sum score (score range 0 to 20) 3 (0 to 18)
Grip strength values with the Vigorimeter (score range
0 to 160 kPa)
Right hand 65 (0 to 158)
Left hand 62 (0 to 160)
Overall disability sum score (score range 0 to 12)
At entry 4 (0 to 11)
Second visit 4 (0 to 12)
Third visit 3 (0 to 12)
f Score (score range 0 to 5) 2 (1 to 4)
Rankin score (score range 0 to 5) 2 (0 to 4)
Longitudinal group of patients (n = 20; GBS 7, CIDP 13)
Age at start of the study (years) 54 (15 to 70)
Overall disability sum score (score range 0 to 12)
At entry 5 (3 to 11)
At 12 weeks of follow up 3 (0 to 10.5)
At 26 weeks of follow up 2.5 (0 to 9.5)
At 40 weeks of follow up 2 (0 to 9)
At 52 weeks of follow up 2 (0 to 9)
Values are median (range).
CIDP, chronic inflammatory demyelinating polyneuropathy; GBS,
Guillain–Barré syndrome; INCAT, inflammatory neuropathy cause
and treatment group; MGUSP, polyneuropathy associated with a
monoclonal gammopathy of undetermined significance.
Table 3 Validity and reliability analyses of the overall disability sum score (ODSS)
in a stable group of patients with immune mediated polyneuropathies (n=113)
“Experienced” couple of
examiners (couple No 1; 45
patients)
“Variable” couples of examiners
(couples Nos 2–28; 68 patients)
p<0.002 for all associations p<0.0001 for all associations
Validity Spearman rank correlation
coefficient (r)
Spearman rank correlation coefficient
(r)
Overall disability sum score versus:
MRC sum score 0.45 0.71
INCAT sensory sum score 0.41 0.56
Grip strength by the Vigorimeter
Right hand 0.54 0.70
Left hand 0.53 0.74
f Score 0.78 0.74
Rankin 0.78 0.79
Reliability Intraclass correlation
coefficient (R)
Intraclass correlation
coefficient (R)
Overall disability sum score:
Interobserver agreements 0.95 0.90
Intraobserver agreements 0.95 0.93
Only the absolute scores in the validity study are presented.
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course of oral prednisone and also showed improvement. The
patients with Guillain–Barré syndrome did not show any
deterioration during follow up and improved gradually over
time.
After initial improvement, all 12 CIDP patients who were
responsive to intravenous immunoglobulin needed continued
interval treatment (0.4 g/kg/d for one to two days at intervals
of three to 21 weeks) to maintain their earlier improvement.
Ultimately, all patients showed a decrease in their degree of
impairment and an improvement in functional ability during
follow up. Improvement in the longitudinal group resulted in
a general reduction in the ODSS values, indicating improve-
ment, with median values of 3, 2.5, 2, and 2 at weeks 12, 26, 40,
and 52, respectively, compared with the median entry value of
5 (Wilcoxon signed-rank test: p < 0.0008 for all comparisons).
Good SRM scores were obtained for the ODSS in these
patients (1.2, 1.5, 1.4, and 1.4 at weeks 12, 26, 40, and 52,
respectively). The patients graded their clinical condition 53
times as “deteriorating,” 38 times as “stable,” and 110 times as
“improving.” These values were significantly associated with
the ODSS changes obtained serially in these patients (random
effects linear regression analyses: R = 0.66; p = 0.008).
Comparative study
The MRC sum score was the strongest predictor of disability
compared with grip strength (Vigorimeter) and the sensory
sum score. Univariate linear regression analyses were as
follows:
• on ODSS: MRC sum score, R2 = 0.45; grip strength,
R2 = 0.40; sensory sum score, R2 = 0.21;
• on f score: MRC sum score, R2 = 0.43; grip strength,
R2 = 0.34; sensory sum score, R2 = 0.16;
• on the Rankin scale: MRC sum score, R2 = 0.34; grip
strength, R2 = 0.24; sensory sum score, R2 = 0.14.
Overall, a higher proportion of variance in disability,
explained by impairment measures, was captured by the
ODSS than by the f score and the Rankin scale (fig 1).
DISCUSSION
In this study, we show that clinimetric requirements—such as
being easily applicable, valid, reliable, and responsive to clini-
cal changes over time—were met by the ODSS in patients with
immune mediated sensory-motor polyneuropathies.15–18 This
scale highlights problems not only with walking but also with
daily arm activities. Its concept is therefore more comprehen-
sive than the widely used Hughes’ functional grading scale
(f score) and the Rankin scale, which are mainly directed
towards mobility and do not provide information on arm
function.4 6 In addition, general loss of strength and sensory
deficits leading to disability were better monitored by the
ODSS than by the f score or the Rankin scale. It therefore
appears that the ODSS is to be preferred for evaluating
disability in these disorders.
The impairment variables recorded by the ODSS explained
two thirds of the disability. This finding implies that other
forms of impairment should be considered in future studies as
contributors to disability. For example, variables such as gen-
eral fatigue and depression have been suggested as important
events in patients with immune mediated polyneuropathies
which may lead to functional deficit.27–29 Lennon and
associates reported six reasons for persistent disability in
patients with Guillain–Barré syndrome.29 These were: muscle
weakness, sensory dysfunction, contractures, fatigue, other
medical conditions, and psychological factors such as anxiety,
depression, and lack of motivation.29
In our study, weakness—as measured by the MRC sum
score—was the most important independent explanatory fac-
tor in the patients’ level of disability. This finding is consistent
with a recent paper addressing outcome in various forms of
polyneuropathy.30
With respect to the aims of the current study, some further
methodological issues should be addressed. First, the SRM
scores obtained for the ODSS only showed within-group
responsiveness. It is not clear whether substantial discrimina-
tive responsiveness scores would be obtained for the ODSS
when evaluating various groups of patients—for example, in a
trial setting comparing a placebo versus a treated group.31 Sec-
ond, univariate and multivariate linear regression analyses of
the f score and Rankin scale were performed, despite the fact
that these outcome measures are ordinal constructs. An ordi-
nal logit estimation model—as described by the program
“ologit” in Stata 6.0—was also applied on these ordinal
variables, but as the description of these analyses was rather
complex and the results quite similar to the linear regression
studies, we decided to present the data in the current form for
clarity. Third, despite having good validity, reliability, and
responsiveness, future studies should determine whether the
ODSS has greater responsiveness scores than other validated
and reliable disability measures.31 This is important, as the
power of a study is directly linked to the responsiveness of the
applied measure (greater responsiveness corresponding to
greater power).31
Conclusions
We have demonstrated the simplicity, validity, reliability, and
responsiveness of the overall (arm plus leg) disability sum
score in patients with immune mediated polyneuropathies.
Impairment leading to disability was better monitored by the
ODSS than by the other disability measures tested. Thus we
Figure 1 Level of disability explained by impairment variables. In the stable group (n=113), multivariate regression analyses were performed
of the disability scales separately (overall disability sum score (ODSS), Hughes’ functional grading scale (f score), or Rankin scale; dependent
variable) on the group of impairment measures (MRC sum score, INCAT sensory sum score, and grip strength by the Vigorimeter; independent
variable). The aim was to determine which disability measure most adequately identified impairment leading to disability (that is, which
disability measures have the strongest association with the group of impairment scales). The predicted values were obtained from these
regressions. Only results that include the right hand grip strength values are presented, as these were similar to the regressions incorporating
the left hand values.
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suggest that the ODSS should be used to monitor disability in
immune mediated polyneuropathies.
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